The higher cancer-specific benefit in the group of patients with PD-L1 from 0% to 50% may seem counterintuitive at first glance, given that the response rate for NSCLC with PD-L1 greater than 50% is much higher than for NSCLC with PD-L1 between 0% and 50%. The gene discussed is CD274; the disease is non-small cell lung carcinoma.